+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Pharmacovigilance Market, By Clinical Trial Phase (Pre-Clinical, Phase 1, Phase 2, Phase 3, and Phase 4), By Method, By Service Provider, By Process Flow, By Therapeutic Area, By End-User, By Region, Forecast & Opportunities, 2026

  • PDF Icon

    Report

  • 111 Pages
  • October 2021
  • Region: Global
  • TechSci Research
  • ID: 5457879
Free Webex Call
10% Free customization
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

Global pharmacovigilance market is anticipated to witness double digit CAGR during the forecast period owing to the increasing drug consumption and drug developments around the globe. Growing prevalence of chronic diseases such as oncology, diabetes, and others has created the need for advanced and more effective pharmaceutical drugs. Keeping in view the chances of Adverse Drug Reactions (ADR) and drug toxicity, healthcare companies are continuously incorporating pharmacovigilance services. Moreover, numerous consumer health protection acts across various regions are further propelling the growth of this market.

Pharmacovigilance is concerned with identifying the hazards associated with pharmaceutical products and minimizing the risk of any harm that may come to patients. The service helps in finding the new safety concerns and evaluating the already known risks. It also helps in keeping a watch on the benefit risk balance of a drug. Any change in the benefit risk ratio will alter the safety profile of the drug.

Global pharmacovigilance market can be segmented based on clinical trial phase, method, service provider, end-user and region. Based on service provider, the market is categorized into in-house and contract outsourcing. Among them, the contract outsourcing service provider dominated the market in 2020 and is expected to dominate the market during the forecast period owing to the fact that it eliminates the risk of business overhead costs and is thus, being increasingly adopted by healthcare companies

Regionally, Asia-Pacific dominates the market and is expected to undergo highest CAGR until 2026 owing to stringent healthcare regulations across the region. The region has also a large patient pool, which is leading to increasing number of clinical trials. Also, countries such as India and China have large clinical research spaces and offer attractive opportunities to healthcare companies.

Major companies operating in global pharmacovigilance market include IBM Corporation, Accenture Plc, Linical Accelovance, Cognizant Technology Solutions Corporation, Laboratory Corporation of America Holdings, ArisGlobal LLC, ICON plc, Capgemini SE, Parexel International Corporation, Wipro Ltd, United BioSource Corporation, BioClinica Inc., TAKE Solutions Ltd., ITClinical, Foresight Group International AG and others. The companies are focusing on research and development activities to offer better pharmacovigilance services and increase their global market share.

Years considered for this report:

  • Historical Years: 2016-2019
  • Base Year: 2020
  • Estimated Year: 2021
  • Forecast Period: 2022-2026

Objective of the Study:

  • To analyze and forecast the market size of global pharmacovigilance market.
  • To forecast global pharmacovigilance market based on clinical trial phase, method, service provider, end-user, company and regional distribution.
  • To identify drivers and challenges for global pharmacovigilance market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global pharmacovigilance market.
  • To identify and analyze the profile of leading players operating in the global pharmacovigilance market.

The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of service providers across the globe. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the service providers which could not be identified due to the limitations of secondary research.

The publisher calculated global pharmacovigilance market size using a bottom-up approach, where data for various end user industries and its application across various product types was recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used.

Key Target Audience:

  • Pharmacovigilance service providers, pharmaceutical companies and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to pharmacovigilance
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as pharmacovigilance companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:


In this report, global pharmacovigilance market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Pharmacovigilance Market, By Clinical Trial Phase

  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

Global Pharmacovigilance Market, By Method

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Global Pharmacovigilance Market, By Service Provider

  • In-House
  • Contract Outsourcing

Global Pharmacovigilance Market, By Process Flow

  • Case Data Management
  • Signal Detection
  • Risk Management System
  • Global Pharmacovigilance Market, By Therapeutic Area
  • Oncology
  • Neurology
  • Cardiology
  • Others

Global Pharmacovigilance Market, By End-User

  • Pharmaceutical & Biotechnology Companies
  • Medical Device Manufacturers
  • Others

Global Pharmacovigilance Market, By Region

  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • North America
  • United States
  • Mexico
  • Canada
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape


Company Profiles: Detailed analysis of the major companies present in global pharmacovigilance market.

Available Customizations:


With the given market data, the publisher offers customizations according to a company’s specific needs.


This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview2. Research Methodology3. Impact of COVID-19 on Global Pharmacovigilance Market4. Executive Summary5. Voice of Customer
6. Global Pharmacovigilance Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Clinical Trial Phase (Pre-Clinical, Phase 1, Phase 2, Phase 3, and Phase 4)
6.2.2. By Method (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining)
6.2.3. By Service Provider (In-House, Contract Outsourcing)
6.2.4. By Process Flow (Case Data Management, Signal Detection, Risk Management System)
6.2.5. By Therapeutic Area (Oncology, Neurology, Cardiology, Others)
6.2.6. By End-User (Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Others)
6.2.7. By Company (2021)
6.2.8. By Region
6.3. Product Market Map
7. Asia-Pacific Pharmacovigilance Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Clinical Trial Phase
7.2.2. By Method
7.2.3. By Service Provider
7.2.4. By Process Flow
7.2.5. By Therapeutic Area
7.2.6. By End-User
7.2.7. By Country
7.3. Asia-Pacific: Country Analysis
7.3.1. China Pharmacovigilance Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Clinical Trial Phase
7.3.1.2.2. By Method
7.3.1.2.3. By Service Provider
7.3.1.2.4. By End-User
7.3.2. India Pharmacovigilance Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Clinical Trial Phase
7.3.2.2.2. By Method
7.3.2.2.3. By Service Provider
7.3.2.2.4. By End-User
7.3.3. Japan Pharmacovigilance Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Clinical Trial Phase
7.3.3.2.2. By Method
7.3.3.2.3. By Service Provider
7.3.3.2.4. By End-User
7.3.4. South Korea Pharmacovigilance Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Clinical Trial Phase
7.3.4.2.2. By Method
7.3.4.2.3. By Service Provider
7.3.4.2.4. By End-User
7.3.5. Australia Pharmacovigilance Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Clinical Trial Phase
7.3.5.2.2. By Method
7.3.5.2.3. By Service Provider
7.3.5.2.4. By End-User
8. Europe Pharmacovigilance Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Clinical Trial Phase
8.2.2. By Method
8.2.3. By Service Provider
8.2.4. By Process Flow
8.2.5. By Therapeutic Area
8.2.6. By End-User
8.2.7. By Country
8.3. Europe: Country Analysis
8.3.1. France Pharmacovigilance Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Clinical Trial Phase
8.3.1.2.2. By Method
8.3.1.2.3. By Service Provider
8.3.1.2.4. By End-User
8.3.2. Germany Pharmacovigilance Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Clinical Trial Phase
8.3.2.2.2. By Method
8.3.2.2.3. By Service Provider
8.3.2.2.4. By End-User
8.3.3. United Kingdom Pharmacovigilance Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Clinical Trial Phase
8.3.3.2.2. By Method
8.3.3.2.3. By Service Provider
8.3.3.2.4. By End-User
8.3.4. Italy Pharmacovigilance Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Clinical Trial Phase
8.3.4.2.2. By Method
8.3.4.2.3. By Service Provider
8.3.4.2.4. By End-User
8.3.5. Spain Pharmacovigilance Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Clinical Trial Phase
8.3.5.2.2. By Method
8.3.5.2.3. By Service Provider
8.3.5.2.4. By End-User
9. North America Pharmacovigilance Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Clinical Trial Phase
9.2.2. By Method
9.2.3. By Service Provider
9.2.4. By Process Flow
9.2.5. By Therapeutic Area
9.2.6. By End-User
9.2.7. By Country
9.3. North America: Country Analysis
9.3.1. United States Pharmacovigilance Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Clinical Trial Phase
9.3.1.2.2. By Method
9.3.1.2.3. By Service Provider
9.3.1.2.4. By End-User
9.3.2. Mexico Pharmacovigilance Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Clinical Trial Phase
9.3.2.2.2. By Method
9.3.2.2.3. By Service Provider
9.3.2.2.4. By End-User
9.3.3. Canada Pharmacovigilance Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Clinical Trial Phase
9.3.3.2.2. By Method
9.3.3.2.3. By Service Provider
9.3.3.2.4. By End-User
10. South America Pharmacovigilance Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Clinical Trial Phase
10.2.2. By Method
10.2.3. By Service Provider
10.2.4. By Process Flow
10.2.5. By Therapeutic Area
10.2.6. By End-User
10.2.7. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Pharmacovigilance Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Clinical Trial Phase
10.3.1.2.2. By Method
10.3.1.2.3. By Service Provider
10.3.1.2.4. By End-User
10.3.2. Argentina Pharmacovigilance Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Clinical Trial Phase
10.3.2.2.2. By Method
10.3.2.2.3. By Service Provider
10.3.2.2.4. By End-User
10.3.3. Colombia Pharmacovigilance Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Clinical Trial Phase
10.3.3.2.2. By Method
10.3.3.2.3. By Service Provider
10.3.3.2.4. By End-User
11. Middle East and Africa Pharmacovigilance Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Clinical Trial Phase
11.2.2. By Method
11.2.3. By Service Provider
11.2.4. By Process Flow
11.2.5. By Therapeutic Area
11.2.6. By End-User
11.2.7. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Pharmacovigilance Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Clinical Trial Phase
11.3.1.2.2. By Method
11.3.1.2.3. By Service Provider
11.3.1.2.4. By End-User
11.3.2. Saudi Arabia Pharmacovigilance Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Clinical Trial Phase
11.3.2.2.2. By Method
11.3.2.2.3. By Service Provider
11.3.2.2.4. By End-User
11.3.3. UAE Pharmacovigilance Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Clinical Trial Phase
11.3.3.2.2. By Method
11.3.3.2.3. By Service Provider
11.3.3.2.4. By End-User
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Competition Outlook
14.2. Company Profiles
14.2.1. IBM Corporation
14.2.2. Accenture Plc
14.2.3. Linical Accelovance
14.2.4. Cognizant Technology Solutions Corporation
14.2.5. Laboratory Corporation of America Holdings
14.2.6. ArisGlobal LLC
14.2.7. ICON plc
14.2.8. Capgemini SE
14.2.9. Parexel International Corporation
14.2.10. Wipro Ltd
14.2.11. United BioSource Corporation
14.2.12. BioClinica Inc.
14.2.13. TAKE Solutions Ltd.
14.2.14. ITClinical
14.2.15. Foresight Group International AG
15. Strategic Recommendations16. About the Publisher & Disclaimer

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • IBM Corporation
  • Accenture Plc
  • Linical Accelovance
  • Cognizant Technology Solutions Corporation
  • Laboratory Corporation of America Holdings
  • ArisGlobal LLC
  • ICON plc
  • Capgemini SE
  • Parexel International Corporation
  • Wipro Ltd
  • United BioSource Corporation
  • BioClinica Inc.
  • TAKE Solutions Ltd.
  • ITClinical
  • Foresight Group International AG